Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedJul 22, 2020Metformin Hydrochloride Extended-Release Tablets USP 1000 mgCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelLupin Pharmaceuticals Inc. · D-1383-2020Class IITerminatedJul 22, 2020Metformin Hydrochloride Extended-release Tablets USP 500 mgCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelLupin Pharmaceuticals Inc. · D-1382-2020Class IIITerminatedJul 15, 2020TecfideracGMP deviations: one lot of the product was distributed to US Markets despite being rejected during in-process control.Biogen MA Inc. · D-1381-2020Class IITerminatedJul 15, 2020CetrotideDefective Container: Market complaints of missing rubber stoppers from drug vial. Missing rubber stoppers could lead to lack of sterility assurance.EMD Serono, Inc. · D-1379-2020Class IIITerminatedJul 15, 2020Nystatin Oral SuspensionFailed impurities/degradation products; Presence of an impurity peak that exceeds the approved specification.VistaPharm, Inc. · D-1378-2020Class IIITerminatedJul 15, 2020Nystatin Oral SuspensionFailed impurities/degradation products; Presence of an impurity peak that exceeds the approved specification.VistaPharm, Inc. · D-1377-2020Class IIITerminatedJul 15, 2020Brimonidine Tartrate Opthalmic Solution 0.2%Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.Somerset Therapeutics LLC · D-1375-2020Class IIITerminatedJul 15, 2020Brimonidine Tartrate Opthalmic Solution 0.2%Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.Somerset Therapeutics LLC · D-1374-2020Class IIITerminatedJul 15, 2020Brimonidine Tartrate Opthalmic Solution 0.2%Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.Somerset Therapeutics LLC · D-1373-2020Class IIITerminatedJul 8, 2020ZilrettaTemperature Abuse: Product was stored at room temperature longer than 6 weeks and was inadvertently distributed instead of discardedFlexion Therapeutics, Inc. · D-1376-2020Class IITerminatedJul 8, 2020Metformin HCl Extended Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.Preferred Pharmaceuticals, Inc. · D-1364-2020Class ITerminatedJul 8, 2020Minoxidil/Biotin/Spironolactone 1.25/5/25 mg capsuleSuper-potent Drug: This recall has been initiated due to the elevated presence of minoxidil and biotin.MasterPharm LLC · D-1363-2020Class IITerminatedJul 8, 2020Childrens Dimetapp Cold & CoughDefective Delivery System: the dosing cups are missing graduations applicable to certain age groups.Glaxosmithkline Consumer Healthcare Holdings · D-1362-2020Class IITerminatedJul 8, 2020Childrens Robitussin Honey Cough and Chest Congestion DMDefective Delivery System: the dosing cups are missing graduations applicable to certain age groups.Glaxosmithkline Consumer Healthcare Holdings · D-1361-2020Class IITerminatedJul 8, 2020Metformin Hydrochloride Extended-Release TabletsCGMP Deviation: Potential presence of Nitrosodimethylamine (NDMA) Impurity above the established levels.The Harvard Drug Group · D-1360-2020Class IITerminatedJul 8, 2020Koala Hand SanitizerSubpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.Beaming White Llc · D-1359-2020Class IITerminatedJul 8, 2020Koala Hand SanitizerSubpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.Beaming White Llc · D-1358-2020Class IITerminatedJul 8, 2020Koala Hand SanitizerSubpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.Beaming White Llc · D-1357-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1393-2020Class IIITerminatedJul 1, 2020Nabumetone TabletsLabeling Not Elsewhere Classified: The statement Pharmacist: Dispense with the accompanying Medication Guide was not included on the carton label.American Health Packaging · D-1372-2020Class IITerminatedJul 1, 2020Clozapine Tablets USP tabletPresence of foreign tablet: Consumer complaint of Clozapine Tablets 50mg being present in 500 count bottles of Clozapine Tablets USP 100mg.Aurobindo Pharma USA Inc. · D-1370-2020Class IIITerminatedJul 1, 2020Timolol Maleate Sterile Opthalmic SolutionLabeling: Label mix-up: A case of Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml, had the outer carton for Timolol Maleate Sterile Ophthalmic solution USP...Rising Pharmaceuticals, Inc. · D-1368-2020Class IIITerminatedJul 1, 2020Timolol Maleate USPLabeling: Label mix-up: A case of Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml, had the outer carton for Timolol Maleate Sterile Ophthalmic solution USP...Rising Pharmaceuticals, Inc. · D-1367-2020Class IITerminatedJul 1, 2020Time-Cap LabsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelMarksans Pharma Limited · D-1356-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1354-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1353-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1352-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1351-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1350-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1349-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1348-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1347-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1345-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1344-2020Class IIOngoingJul 1, 2020amneal Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAmneal Pharmaceuticals of New York, LLC · D-1343-2020Class IIITerminatedJul 1, 2020Duavee (conjugated estrogens/bazedoxifene) tablets 0.45/20 mgFailed Dissolution SpecificationsPfizer Inc. · D-1342-2020Class IITerminatedJul 1, 2020Aripiprazole TabletsLabeling: Label mix up: Bottles labeled as aripiprazole 2 mg, 30 count had aripiprazole 5 mg tablets, 100 count.Alembic Pharmaceuticals Limited · D-1341-2020Class IITerminatedJul 1, 2020Nystatin CreamSubpotent Drug: Out of specification for assay at the 9-month interval for Nystatin Cream, USP.Crown Laboratories · D-1339-2020Class IITerminatedJul 1, 2020Nystatin CreamSubpotent Drug: Out of specification for assay at the 9-month interval for Nystatin Cream, USP.Crown Laboratories · D-1338-2020Class IITerminatedJul 1, 2020Soft Whisper by Powerstick Dandruff ShampoocGMP Deviations: Soft Whisper Dandruff Shampoo was produced with water that failed USP specifications.A.P. Deauville, LLC · D-1337-2020